Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2011-12-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 72
- Registration Number
- NCT00681928
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 170
- Registration Number
- NCT00673335
- Locations
- 🇫🇷
Hopital Arnaud de Villeneuve, Montpellier, France
🇫🇷Centre Hospitalier General de Niort, Niort, France
🇫🇷Centre Catherine de Sienne, Nantes, France
Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 213
- Registration Number
- NCT00651976
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Vanderbilt-Ingram Cancer Center, One Hundred Oaks, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 52
- Registration Number
- NCT00634634
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Cooper Hospital/University Medical Center, Voorhees, New Jersey, United States
Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00634894
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2012-08-09
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT00611715
- Locations
- 🇺🇸
Jackson-Madison County Hospital, Jackson, Tennessee, United States
🇺🇸The Jones Clinic - Germantown, Germantown, Tennessee, United States
🇺🇸Tennessee Cancer Specialists, Knoxville, Tennessee, United States
Letrozole vs. Clomiphene Citrate in Patients With Anovulatory Infertility
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2008-02-07
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 55
- Registration Number
- NCT00610077
- Locations
- 🇮🇳
IVF Centre, Chembur,, Mumbai-, Maharashtra, India
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 394
- Registration Number
- NCT00601900
- Locations
- 🇺🇸
Longmont United Hospital, Longmont, Colorado, United States
🇺🇸Dublin Hematology Oncology Care PC, Dublin, Georgia, United States
🇺🇸Piedmont Fayette Hospital, Fayetteville, Georgia, United States
Study of Breast Cancer Prevention by Letrozole in High Risk Women
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Carol Fabian, MD
- Target Recruit Count
- 55
- Registration Number
- NCT00579826
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 4
- Registration Number
- NCT00573755
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.